Valneva announces publication of first Phase II data of tuberculosis vaccine candidate formulated with IC31® adjuvant

Clinical trial in HIV-infected adults showed good safety and immunogenicity

To download the press release, click here.


Source: Valneva SE 

To subscribe to the Weekly Newsletter of new posts, enter your email here:


News

By Valneva SE

Published: Dec. 11, 2014, 10:44 p.m.

Last updated: Dec. 12, 2014, 3:47 a.m.

Print Share